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Abstract
Leucine-rich repeat kinase 2 (LRRK2), a large protein kinase containing multi-functional domains, has been identified as the
causal molecule for autosomal-dominant Parkinson’s disease (PD). In the present study, we demonstrated for the first time
that (i) LRRK2 interacts with tau in a tubulin-dependent manner; (ii) LRRK2 directly phosphorylates tubulin-associated tau,
but not free tau; (iii) LRRK2 phosphorylates tau at Thr181 as one of the target sites; and (iv) The PD-associated LRRK2
mutations, G2019S and I2020T, elevated the degree of tau-phosphorylation. These results provide direct proof that tau is a
physiological substrate for LRRK2. Furthermore, we revealed that LRRK2-mediated phosphorylation of tau reduces its
tubulin-binding ability. Our results suggest that LRRK2 plays an important role as a physiological regulator for
phosphorylation-mediated dissociation of tau from microtubules, which is an integral aspect of microtubule dynamics
essential for neurite outgrowth and axonal transport.
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Introduction
Tau is a microtubule-associated protein found predominantly in
the central nervous system and expressed mainly in neuronal
axons [1]. Tau has six splicing isoforms, ranging in size from 352
to 441 amino acid residues [2]. The shortest tau isoform is
expressed only in fetal brain, and the other five are expressed
developmentally in the adult brain [3]. Tau drives neurite
outgrowth by promoting the assembly of microtubules, which is
critical for the establishment of neuronal cell polarity [4]. In
Alzheimer’s disease and other neurodegenerative diseases, such as
frontotemporal dementia and parkinsonism linked to chromosome
17 (FTDP-17), tau becomes highly phosphorylated and forms a
paired helical filament [3]. Hyperphosphorylated tau-based
neurofibrillary lesions are the predominant brain pathology in
these disorders, which are referred to collectively as ‘‘tauopathies’’
[5].
Leucine-rich repeat kinase 2 (LRRK2) is the causative molecule
of familial Parkinson’s disease (PD) [6,7]. It is a 286-kDa protein
containing an N-terminal leucine-rich repeat, a Ras of complex
protein (ROC) GTPase domain, a C-terminal of the Roc region, a
kinase domain, and a WD40 domain [8]. LRRK2 is widely
expressed in many organs, such as the brain, heart, kidney, lung,
and liver [9,10]. It is also expressed in some immune cells [11,12].
In the brain, LRRK2 is expressed in the cerebral cortex, medulla,
cerebellum, spinal cord, putamen, and substantia nigra. Accumu-
lating evidence [13] indicates that (i) wild-type LRRK2 exhibits
protein kinase activity, and undergoes autophosphorylation; (ii) the
kinase activity of LRRK2 has a strict requirement for binding of
guanosine triphosphate (GTP), whereas intrinsic GTPase activity
is exerted independently of the kinase activity; and (iii) the
phosphorylation activity of LRRK2 is enhanced significantly by
the G2019S mutation linked to the pathogenesis of PD. However,
neither the physiological function of LRRK2 including the true
substrate(s) nor the molecular mechanisms of neurodegeneration
caused by LRRK2 mutations has yet been elucidated.
It has been reported that neurite length is reduced in LRRK2-
deficient cultured mouse neurons [14]. In contrast, another study
found that neurite length and branching were increased by
LRRK2-knockdown or LRRK2-kinase inactivation and reduced
by PD-associated LRRK2 mutations [15]. Furthermore, studies of
the kinase-active mutant G2019S-LRRK2 have demonstrated
common morphological changes in neurites, i.e., i) neurite
shortening due to G2019S-LRRK2 expression in differentiated
SH-SY5Y cells [16,17], ii) shortened neurites of cultured neurons
derived from G2019S-LRRK2 transgenic mice [18], and iii)
markedly reduced neurite complexity of cultured dopaminergic
neurons in the brains of aged G2019S-LRRK2 transgenic mice
[19]. LRRK2 might regulate neuronal morphology through
interaction with, and phosphorylation of, b-tubulin [14]. In
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phosphorylation of tau, mislocalization of tau, and phospho-tau-
positive inclusions in neurons of animal models and patients with
LRRK2 abnormality [14,15,20–23] strongly suggest that LRRK2
may modulate microtubule dynamics by controlling the phos-
phorylation status of tau. However, because no experimental
evidence proving that LRRK2 directly phosphorylates tau has
been reported, the contribution of LRRK2 to phosphorylation of
tau is thought to be indirect, occurring via other kinases such as
glycogen synthase kinase-3b (GSK-3b) and thousand-and-one
amino acid kinase 3 (TAOK3) [15,23,24]. In the present study, we
demonstrate that LRRK2 directly phosphorylates tau in the
presence of tubulin and facilitates dissociation of tau from tubulin,
thus indicating that LRRK2 is of considerable physiological
importance in microtubules dynamics.
Materials and Methods
Chemicals
[c-
32P]ATP (3000 Ci/mmol) was obtained from Perkin Elmer
Inc. (Massachusetts, USA); dithiothreitol (DTT) was from Wako
Pure Chemical (Osaka, Japan); recombinant N-terminal glutathi-
one S-transferase (GST)-tagged LRRK2 (GST–LRRK2, aa 970–
2527; wild-type, R1441C mutant, G2019S mutant, and I2020T
mutant) were from Invitrogen (San Diego, USA); recombinant tau
protein 441 (tau, aa 1–441) was from Signal Chem Pharmaceu-
ticals (Richmond, Canada); purified porcine tubulin was from
Cytoskeleton (Denver, USA); and bovine myelin basic protein
(MBP) was from Sigma-Aldrich (Missouri, USA).
Antibodies
Anti-GST was obtained from Advanced Targeting Systems (San
Diego, USA); horseradish peroxidase (HRP)-conjugated anti-V5
and anti-V5 antibody-conjugated agarose beads were from
Invitrogen (Camarillo, USA); rabbit anti-LRRK2 monoclonal
antibody MJFF2 (c41-2) was from Epitomics (Burlingame, USA);
anti-human tau (HT7), anti-phosphorylated Thr residues of tau,
AT270 (Thr181), AT8 (Thr205), AT100 (Thr212), and AT180
(Thr231) were from Thermo Fisher Scientific (Fremont, USA);
anti-beta tubulin for Western analysis was from Abcam (Cam-
bridge, UK); and anti-beta-III tubulin for immunofluorescent
staining was from R&D Systems (Minneapolis, USA). HRP-
conjugated goat anti-mouse IgG and HRP donkey anti-rabbit IgG
were from Biolegend (San Diego, USA) and Alexa Fluor 555 goat
anti-mouse IgG was from Cell Signaling (Danvers, USA).
Cell culture and Immunoprecipitation
A clone (WT4-D33) of the human neuroblastoma cell line SH-
SY5Y, stably expressing LRRK2 with a C-terminal V5-tag and a
vector control clone (NEO) expressing only the neomycin resistant
gene have been described previously [25]. The cells were cultured
in Dulbecco’s modified Eagle medium (DMEM) nutrient mixture
F-12 HAM (Sigma) supplemented with 10% FCS and antibiotics
at 37uC and 5% CO2 in a humidified atmosphere, as described
previously [25–27]. The cells were lysed in lysis buffer [10 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1% NP-40, protease and phosphatase inhibitor cocktail (Roche,
Mannheim, Germany)]. The cell lysates were incubated with anti-
V5 antibody-conjugated or normal rabbit IgG-conjugated agarose
beads overnight at 4uC. The beads were then washed three times
with lysis buffer, and precipitated proteins were detected by
Western blotting using the antibodies indicated in the figure
legends.
In vitro GST pull-down assay
Recombinant GST-LRRK2 or GST alone was mixed with
porcine tubulin and incubated with glutathione agarose beads
overnight at 4uCi n1 0 0 mL of TNE buffer [50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1% (v/v) NP-40, 1 mM EDTA]. In
another experiment,recombinant tau was mixed withGST-LRRK2
or GST alone and incubated with glutathione agarose beads in the
presence or absence of tubulin in 100 mL of TNE buffer overnight at
4uC. After centrifugation, the supernatant was removed, and the
beads were washed three times with TNE buffer. The bound
proteins were eluted from the beads by boiling in 50 mLo fS D S -
PAGE sample buffer. The GST-LRRK2 (or GST alone), tau and
tubulin in the eluted samples were detected by Western blotting.
In vitro kinase assay for LRRK2
Recombinant tau was used as a substrate for GST-LRRK2.
Briefly, 2 mg of tau was incubated with 50 ng of GST-LRRK2
(either wild-type, R1441C mutant, G2019S mutant, or I2020T
mutant) in 25 mL of standard reaction mixture [40 mM Tris-HCl
(pH 7.6), 2 mM DTT, 10 mM Mg
2+,3mCi of [c-
32P]ATP] in the
presence or absence of tubulin (1 mg). After incubation for 30 min
at 30uC, the reaction was stopped by adding SDS-PAGE sample
buffer and boiling. The
32P-labeled proteins in the reaction
mixture were detected by autoradiography followed by SDS-
PAGE, as described previously [27–29].
Phosphoamino acid and phosphopeptide analysis of tau
Detection of phosphoamino acids and phosphopeptides of
32P-
labeled tau was performed by two-dimensional TLC as described
previously [28,29].
Phosphorylation of tau and neurite outgrowth in LRRK2-
knockdown cells
For knockdown of LRRK2 expressed by the SH-SY5Y clone
WT4-D33 and a vector control clone NEO, cells were transfected
with 25 mer of StealthH RNAi for LRRK2 (59-GAGCUGCUC-
CUUUGAAGAUACUAAA-39; Invitrogen) or with an RNAi-
control with the scrambled sequence using FuGENEHHD
Transfection Reagent (Roche), as described previously [27]. After
48 h of transfection, cell lysates were prepared and subjected to
Western analysis with antibodies against V5-tag, LRRK2
(MJFF2), phosphorylated tau (Thr181), and non-phosphorylated
tau. For analysis of neurite outgrowth, WT4-D33 and NEO were
first treated with 10 mM all-trans retinoic acid for 72 h, transfected
with the LRRK2-specific RNAi or RNAi-control, cultured for a
further 72 h, and subjected to immunofluorescence staining with
anti-b III tubulin. The length of neurites was analyzed using NIH
ImageJ software (NeuronJ).
Results
Tubulin-dependent interaction of LRRK2 with tau
To examine the possibility that LRRK2 is able to interact with
tau in human neural cells, we first performed a co-immunopre-
cipitation assay. A cell lysate of a SH-SY5Y clone (WT4-D33 [25])
stably overexpressing V5-tagged full length LRRK2 was incubated
with anti-V5 antibody-conjugated agarose beads. The precipitated
proteins were then detected by Western blotting using specific
antibodies against V5-tag, tau and tubulin. We found that both tau
and tubulin were co-precipitated with LRRK2 (Fig. 1A).
To elucidate the relationships among the three interacting
molecules (LRRK2, tubulin, and tau), we performed an in vitro
pull-down assay using recombinant proteins. First, recombinant
LRRK2 Directly Phosphorylates Tau
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presence of specific and direct binding between LRRK2 and
tubulin, consistent with the report by Gillardon [14] (Fig. 1B).
Second, recombinant tau was mixed with GST-LRRK2 in the
presence or absence of tubulin, and then incubated with
glutathione agarose beads. In the presence of tubulin, a large
amount of tau was co-precipitated with LRRK2, whereas in the
absence of tubulin little tau was co-precipitated (Fig. 1C, lane 4 vs
lane 2). These results suggested that LRRK2 was able to bind
tubulin-associated tau but not the free tau molecules.
LRRK2 phosphorylates tubulin-associated tau but not
free tau
We then investigated whether tubulin affects the phosphoryla-
tion of tau by LRRK2. Recombinant tau was incubated with
GST-LRRK2 and [c-
32P]ATP in the presence or absence of
tubulin. We found that LRRK2 markedly phosphorylated tau in
the presence of tubulin, whereas it phosphorylated tau only very
slightly in the absence of tubulin (Fig. 2A). These results indicated
that LRRK2 directly phosphorylated tubulin-associated tau, but
not tubulin-unassociated free tau.
To determine the stoichiometry of tau phosphorylation by
LRRK2, incorporation of
32P into tau was measured after
incubation with LRRK2, tubulin, and radiolabeled ATP. It was
found that about 0.5 mole of phosphate was incorporated into 1
mole of tau (Fig. 2B). This low phosphorylation level was ascribed
to the fact that only tubulin-associated tau, and not free tau, is
phosphorylated by LRRK2. The kinase activity of LRRK2 toward
tubulin-associated tau was approximately three times lower than
that toward known excellent substrates such as tubulin or MBP
under our experimental conditions (Fig. 2C). We further analyzed
the tau-phosphorylation activity of LRRK2 with three PD-
associated mutations: R1441C in the ROC domain, G2019S in
the kinase domain, and I2020T in the kinase domain. We found
that G2019S and I2020T, but not the R1441C mutant LRRK2,
exerted increased tau-phosphorylation activity in comparison with
the wild-type LRRK2 (Fig. 2D). These results indicate that the
phosphorylation of tau is indeed attributable to the kinase activity
of LRRK2, which is influenced by disease-associated mutations.
Identification of phosphorylation site for LRRK2 in tau
Next, we performed phosphoamino acid analysis after full
phosphorylation of tau by GST-LRRK2 using [c-
32P]ATP. Only
the
32P-labeled Thr residue was detected when tau was incubated
with GST-LRRK2 and tubulin, and no phosphorylation of the Ser
or Tyr residue was observed (Fig. 3A). Phosphopeptide mapping of
Figure 1. Tubulin-dependent interaction of LRRK2 with tau. (A) V5-LRRK2 was immunoprecipitated with anti-V5-agarose beads from the V5-
LRRK2-stably-expressing SH-SY5Y clone, WT4-D33. Normal rabbit IgG-conjugated agarose beads were used as a control. The immunoprecipitates
were separated by SDS-PAGE, transferred to PVDF, and analyzed using antibodies against V5-tag, tau, and tubulin. (B) GST (lane 1) and GST-LRRK2
(lane 2) were incubated with porcine tubulin, and a pull-down assay using glutathione-agarose beads was performed. Precipitated proteins were
detected by Western analysis using anti-GST and anti-tubulin antibodies. (C) GST and GST-LRRK2 were incubated with recombinant tau in the
absence (lane 1 and 2) or presence (lane 3 and 4) of porcine tubulin, and a pull-down assay using glutathione-agarose beads was performed.
Precipitated proteins were detected by Western analysis using the indicated antibodies.
doi:10.1371/journal.pone.0030834.g001
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d) (Fig. 3B). These findings suggested that at least four potential
phosphorylation sites (Thr only) of tau are predominantly
phosphorylated by LRRK2 in the presence of tubulin. To identify
the site of tau phosphorylation by LRRK2, we performed Western
analysis using antibodies specific for each of the phospho-Thr
residues, i.e., AT270 (Thr181), AT8 (Thr205), AT100 (Thr212),
and AT180 (Thr231), which are the sites known to be frequently
phosphorylated. We found that Thr181 was phosphorylated by
LRRK2 only in the presence of tubulin (Fig. 3C). These results
indicated that Thr181 is one of the phosphorylation target sites for
LRRK2. In addition, tau may contain three unidentified potential
Figure 2. LRRK2-mediated phosphorylation of tau in the presence of tubulin. (A) Recombinant tau (2 mg) was incubated with GST-LRRK2
(50 ng each) and 3 mCi of [c-
32P]ATP in the absence (lane 1) or presence (lane 2) of purified porcine tubulin (1 mg) for 30 min at 30uC.
32P-Labeled
proteins in the reaction mixture were detected by autoradiography following SDS-PAGE. A Coomassie Brilliant Blue (CBB) post-stained gel image is
shown in the right panel to indicate the identity and amount of LRRK2 and tau in the two lanes. (B) The kinetics of tau phosphorylation by LRRK2 was
measured after incubation for indicated periods at 30uC. The radioactivity of
32P-labeled tau in the presence (N) or absence (#) of tubulin was
determined using a liquid scintillation counter. (C) Equal amounts (2 mg) of tau, tubulin, and MBP were incubated with GST-LRRK2 (50 ng each) and
3 mCi of [c-
32P]ATP for 30 min at 30uC. The radioactivity of
32P-labeled proteins was determined using a liquid scintillation counter. (D) Left: Tau (2 mg)
was incubated with GST-LRRK2 of the wild-type (WT), G2019S, I2020T, or R1441C mutants and 3 mCi of [c-
32P]ATP in the presence of tubulin (1 mg) for
30 min at 30uC. The
32P-labeled proteins in the reaction mixture were detected by autoradiography following SDS-PAGE. CBB post-stained gel images
are shown in the bottom panel to indicate the identity and amount of LRRK2, tau, and tubulin in the lanes. Right: Graphical representation of the
rates of tau phosphorylation by WT, G2019S, I2020T, and R1441C LRRK2. Phosphorylation rates relative to WT-LRRK2 are shown.
doi:10.1371/journal.pone.0030834.g002
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were detected by phosphopeptide mapping.
Effect of overexpression and knockdown of LRRK2 on
phosphorylation of tau (Thr181) and neurite outgrowth
in neuronal cells
To confirm the tau-phosphorylation activity of LRRK2 in
neural cells, we next analyzed a SH-SY5Y clone, WT4-D33,
overexpressing V5-wild-type LRRK2 [25]. Western analysis with
an antibody recognizing both endogenous and transfected
LRRK2 revealed that LRRK2 protein expression by WT4-D33
was about five-fold higher than that in the vector-control clone,
NEO (Fig. 4A). We found that this clone exhibited 1.7-fold higher
tau (Thr181) phosphorylation than the vector-control. Transfec-
tion of LRRK2-specific RNAi into WT4-D33 reduced the level of
LRRK2 protein to 46% in comparison with the use of an RNAi
control. Concordantly, knockdown of LRRK2 resulted in a
significant reduction of tau phosphorylation (Thr181) (76% in
comparison with that of the RNAi control cells) (Fig. 4A). Thus,
the phosphorylation level of tau (Thr181) was increased or
reduced depending on the level of LRRK2 protein in vivo,
suggesting that tau is likely the physiological substrate for LRRK2.
It has been reported that increase of tau phosphorylation at
Thr181 correlate with neurite retraction in SH-SY5Y cells
[30,31]. Therefore, LRRK2 may reduce the neurite length
through phosphorylation of tau at Thr181. To analyze neurite
outgrowth, WT4-D33 and NEO were first treated with retinoic
acid to induce differentiation, and then transfected with the
LRRK2-specific RNAi or RNAi-control. The cells were
immunostained with anti-beta III tubulin, and then the length
of neurites was measured. In the cells transfected with the
RNAi-control, WT4-D33 showed significantly shorter neurites
than NEO. Conversely, the neurite length of each clone was
increased by transfection with the LRRK2-specific siRNA
(Fig. 4B). These results indicate that neurite outgrowth is
influenced by the level of LRRK2 protein, and together with the
above findings, suggest that phosphorylation of tau (Thr181) by
LRRK2 is one of the important regulatory mechanisms for
neurite outgrowth.
Effect of LRRK2-mediated phosphorylation of tau on its
association with tubulin
As the association of tau with tubulin is well known to be
modulated in a phosphorylation-dependent manner, we investi-
gated the effect of LRRK2-mediated phosphorylation on the
tubulin-binding capacity of tau. After full phosphorylation of
recombinant tau by GST-LRRK2 in the presence of tubulin, we
performed a GST pull-down assay. As shown in Fig. 5A,
32P-
phosphorylated tau was not detected in the precipitated fraction
(upper panel), although non-phosphorylated tau was detectable in
this fraction (lower panel). In contrast,
32P-phosphorylated tau was
detected only in the LRRK2-unbound supernatant. Furthermore,
we investigated whether tau phosphorylated at Thr181 interacts
with LRRK2 using a co-immunoprecipitation assay with a WT4-
D33 cell lysate. We found that phosphorylated tau (Thr181) was
not detected in the fraction containing LRRK2, whereas
immunoreactivity for phospho-independent tau and tubulin was
detected in the same fraction (Fig. 5B). These results suggested that
LRRK2-mediated phosphorylation of tau abolished its capacity to
associate with tubulin. On the other hand, binding of tubulin to
LRRK2 was not affected by phosphorylation.
Discussion
In the present study, we found for the first time that LRRK2
directly phosphorylates tubulin-associated tau and reduces its
tubulin-binding ability, whereas LRRK2 does not phosphorylate
the free tau molecule. Thus, LRRK2 would serve as a regulator of
association/dissociation between tau and tubulin (Fig. 6). In
neuronal cells, phosphorylation-dependent dissociation of tau from
tubulin is an integral aspect of microtubule dynamics essential for
neurite outgrowth and axonal transport, although excessive
phosphorylation of tau would negatively regulate its ability to
promote microtubule assembly. Therefore, LRRK2 may play an
important role in neuronal cell function. Importantly, the PD-
associated LRRK2 mutations, G2019S and I2020T, were found to
exert hyper-phosphorylation of tau, thus providing a clue for
clarifying the mechanism of neurodegeneration.
Tau has not been reportedly detected as the LRRK2 binding
protein in other studies involving proteomic analysis [32,33].
Because LRRK2 appears to bind to a wide variety of proteins,
including abundant proteins such as chaperones and actin-related
molecules, it is possible that the relative proportion of tau among
total LRRK2-associated proteins was insufficient for detection in
some cases. In the present study, we focused our analysis on tau
only, and detected it by Western analysis using a specific antibody.
Figure 3. Identification of phosphorylation site for LRRK2 in
tau. (A)
32P-labeled phosphoamino acids of tau fully phosphorylated by
GST-LRRK2 in the presence of tubulin were analyzed by two-
dimensional thin-layer cellulose (TLC) electrophoresis, as described in
Materials and Methods. (B)
32P-labeled tau was separated by SDS-PAGE
and digested with trypsin in the gel. The resulting polypeptides were
separated by TLC electrophoresis (first dimension) and chromatography
(second dimension). The phosphopeptides were loaded at the position
indicated as the origin. (C) Tau was incubated with GST-LRRK2 and
100 mM non-radiolabeled ATP in the presence or absence of tubulin at
30uC for 180 min. The samples were then analyzed by Western blotting
using antibodies specific to the phosphorylated Thr residues of tau.
doi:10.1371/journal.pone.0030834.g003
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associated tau and not to free tau, making it more difficult to be
detected as a specifically LRRK2-associated molecule. Finally, the
LRRK2-overexpressing SH-SY5Y clone from which we prepared
the cell lysate for immunoprecipitation was the neuronal cell line
known to express a higher level of tau than cells of other tissue
types [34].
In the present study, we identified a Thr181 as one of the direct
target sites of tau for LRRK2. It has been shown in mouse models
that the level of tau phosphorylation at Ser202/Thr205 in the
brain was elevated in R1441G and G2019S LRRK2 transgenic
mice and diminished in LRRK2-knockout mice [19–21].
However, we did not detect LRRK2 phosphorylation of tau at
any Ser-residues or at Thr205, nor did we observe any increase in
the phosphorylation level of tau Thr205 upon overexpression of
LRRK2 in SH-SY5Y cells (data not shown). In a Drosophila
model, on the other hand, it has been reported that dopaminergic
neurons of G2019S LRRK2-transgenic flies exhibited hyperpho-
sphorylation of tau at Thr212, which was ascribed to kination by
the activated GSK-3b homologue, and not to direct kination by
LRRK2 [23]. No increase of phosphorylation at either Thr181 or
Thr205 was detected in the transgenic flies. These differences in
the findings of previous studies could be due either to differences in
species, cell sources, or other experimental conditions such as the
levels of expression of LRRK2 and tau. LRRK2 has been reported
to phosphorylate TAOK3, a kinase with high sequence homology
to MARK kinase, suggesting a possibility of LRRK2-mediated
indirect phosphorylation of tau [24].
Figure 4. Effect of overexpression and knockdown of LRRK2 on phosphorylation of tau (Thr181) in neuronal cells and their neurite
outgrowth. (A) Left: A SH-SY5Y clone (WT4-D33) expressing V5-tagged wild-type LRRK2 was transfected with either the LRRK2-specific RNAi or the
RNAi control. After 48 h of transfection, cell lysates were prepared and subjected to Western analysis using antibodies against V5-tag, LRRK2,
phospho-tau (Thr181), and non-phosphorylated tau. A vector control clone (NEO) expressing only the neomycin gene is shown in lane 1. Right:
Graphical representation of the tau (Thr181)-phosphorylation level. (B) Left: WT4-D33 and NEO were treated with 10 mM all-trans retinoic acid for
72 h, transfected with the LRRK2-specific RNAi or RNAi-control, cultured for a further 72 h, and subjected to immunostaining with anti-b III tubulin.
Right: Graphical representation of neurite length measured using NIH ImageJ software. Stars represent statistical comparisons by one-way ANOVA
(n=3 in A and n=50 in B); *: p,0.005, **: p,0.001.
doi:10.1371/journal.pone.0030834.g004
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phorylation of tau enhances its dissociation from tubulin suggest
that this process is one of the important regulatory mechanisms for
microtubule disassembly, which may lead to reduced neurite
outgrowth. In mouse neurons, however, there has been some
controversy as to whether kinase activity of LRRK2 reduces or
Figure 5. Effect of LRRK2-mediated phosphorylation on the ability of tau to bind to tubulin. (A) Recombinant tau (2 mg) was incubated
with GST-LRRK2 (50 ng) and 3 mCi of [c-
32P]ATP in the presence of porcine tubulin (1 mg) at 30uC for 120 min and then a GST pull-down assay was
performed as described in Materials and Methods.
32P-Labeled proteins in the precipitates were detected by autoradiography following SDS-PAGE
(upper panel). Total tau in the same sample was detected by Western blotting analysis using anti-tau antibody (lower panel). (B) V5-LRRK2 was
immunoprecipitated with anti-V5-agarose beads from a WT4-D33 cell lysate. Precipitated proteins were analyzed by Western blotting using
antibodies against V5-tag, phospho-tau (Thr181), non-phospho-epitopes of tau, and tubulin.
doi:10.1371/journal.pone.0030834.g005
Figure 6. LRRK2-mediated regulation of association/dissociation between tau and tubulin. LRRK2 interacts with tubulin-associated tau,
resulting in the formation of a tripartite complex (lower left). This complex induces the phosphorylation of tau by LRRK2 (upper left) and sequentially
induces dissociation of tau from tubulin (upper right). Tau is dephosphorylated by certain protein phosphatases, and the dephosphorylated tau then
recovers its ability to bind with tubulin (lower right).
doi:10.1371/journal.pone.0030834.g006
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reportedly increased by LRRK2-knockdown or LRRK2-kinase
inactivation [15], whereas another study has found a decrease of
neurons differentiated from LRRK2-knockout mouse embryonic
stem cells [14]. Furthermore, kinase active mutant G2019S-
LRRK2 expression in neurons has been reported to markedly
reduced neurite length in comparison with the wild-type and or
kinase-dead mutant [16–19].
Several candidate LRRK2-substrate molecules and various
mechanisms of neurodegeneration caused by LRRK2 mutations
have been reported [8,35], i.e., the actin-cytoskeleton-related
ERM (ezrin/radxin/moesin) whose inappropriate phosphoryla-
tion causes perturbation of cytoskeletal organization [36],
eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) whose
hyperphosphorylation induces dysregulated protein translation
[37], and several signal transduction molecules such as TAOK3,
serine/threonine kinases 3, 24, and 25 [24], Akt1 [27], and
mitogen-activated kinase kinases 3, 4, 6, and 7 [38], whose hypo-
or hyperphosphorylation leads to abnormal signal transduction
that can induce a wide variety of cellular damage, including
activation of the caspase cascade [24,27,36–40]. With regard to
microtubule-related molecules, Gillardon has identified b-tubulin
as the LRRK2 substrate and reported that its increased
phosphorylation by G2019S LRRK2 enhanced microtubule
assembly/stability in the presence of microtubules-associated
proteins [14]. Lin et al. have reported that G2019S LRRK2-
transgenic Drosophila neurons exhibit GSK-3b-mediated hyper-
phosphorylation and mislocalization of tau [23]. The R1441G and
G2019S LRRK2 transgenic mice exhibiting abnormality in
dopamine transmission reportedly have the hyperphosphorylated
tau in their brain [20,21]. The results obtained in the present study
demonstrating that G2019S and I2020T mutant LRRK2 elicit
direct hyperphosphorylation of tau may further support the notion
that impairment of microtubule dynamics plays a crucial role in
the neurodegeneration caused by LRRK2 mutations. In addition,
LRRK2 immunoreactivity has been detected in tau-positive
inclusions in samples of brain tissue affected by various
neurodegenerative disorders [41]. In particular, LRRK2 is closely
associated with tau-positive inclusions in FTDP-17 caused by
N279K tau mutations [42]. It is possible that the LRRK2-
mediated phosphorylation of tau reported here may make an
important contribution to the formation of these pathological
features.
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